Method of treating hepatitis delta virus infection
AssigneesGeorgetown University, Cornell Research Foundation, Inc., University of Georgia Research Foundation, Inc.
InventorsJohn L. Casey, Brent E. Korba, Paul J. Cote, John L. Gerin, Bud C. Tennant, Chung K. Chu
Life of this patent
Estimating the term…
Abstract
A method for the treatment for hepatitis delta infection in a host, that includes administering an effective amount of a nucleoside or a nucleoside analog that suppresses the expression of the hepatitis B surface or preS1 antigen in the host 100-fold or more relative to pretreatment values in vivo; or to not more than 1 microgram per milliliter in vivo. In a preferred embodiment, the nucleoside is L-FMAU, or a pharmaceutically acceptable salt or prodrug thereof.
Claims16
A method for the treatment of hepatitis delta infection comprising administering to a host an effective amount of a β-L nucleoside of the formula
- wherein R is 5-methyl uracil (also referred to as thymine) and R′ is hydrogen, acyl, alkyl, monophosphate, diphosphate, triphosphate, or a phosphate prodrug or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.